ABLi Therapeutics has completed an End of Phase 2 meeting with the FDA, securing support for innovative endpoints in upcoming Phase 3 trials for risvodetinib in Parkinson's disease.
Inhibikase Therapeutics discontinues development of risvodetinib for Parkinson's disease after Phase II trial fails to show significant efficacy despite meeting safety endpoints.
Inhibikase Therapeutics has completed enrollment of 120 participants across 32 U.S. sites in its Phase 2 '201' trial evaluating risvodetinib for untreated Parkinson's disease, with results expected in Q4 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.